Molnupiravir authorisation comes with a condition - further trials in the next three months

According to one of the conditions, as post marketing surveillance the companies will have to submit periodic safety update reports to the drug regulator.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3pD0wqC
via IFTTT